Proprietary Drugs in Development
CelAgace™OraRinse Solution is under clinical development for the treatment of Candida associated oral mucositis. Oral Candidiasis is a yeast infection that commonly is a sequela associated with oral mucositis in immunosuppressed patients following chemotherapy. The product is a combination drug comprising silver citrate complex and acemannan. The product is targeted towards the oncology market.
CelaGel™ Antimicrobial Hydrogel is currently under transition from development as a Class II medical device to a drug. The transition decision followed encouraging early clinical development. Development will target topical treatment of surgical and non-surgical oncology procedures.
CelaEase™ Dermal Gel is in early development studies associated with formulation refinement for the topical treatment of Herpes zoster, commonly known as shingles. Shingles is the re-emergence of the varicella-zoster virus (VZV-chickenpox) in previously infected individuals. Once an individual is infected and the illness resolves, the virus can remain dormant for years before expression as a painful rash. The rash progresses to clear vesicles that once cleared may result in skin discoloration and scarring. Shingles generally occurs on the trunk but can also be associated with the head and face. It is expected that 1 out of every 3 Americans will experience the disease at some point in their life.